



October 8, 2024

Re: Gilead Advancing Access[®] Patient Assistance Program/Medication Assistance Program (PAP/MAP) Update

Dear Healthcare Provider,

We are writing to notify you of an upcoming change to the Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP).

What is changing:

- Considering the broad availability of multiple generic medication options, and/or low enrollment volume, effective January 31, 2025, the Advancing Access program will no longer provide free medication for TRUVADA[®], EMTRIVA[®], TYBOST[®] and COMPLERA[®]. No **new** enrollments into the PAP/MAP free medication programs for TRUVADA[®], EMTRIVA[®], TYBOST[®] and COMPLERA[®] will be accepted after December 31, 2024.
- We will have an exception program for eligible uninsured individuals assigned female at birth who have been prescribed Truvada[®] for HIV prevention who cannot afford a generic alternative. If eligible, these individuals may continue to receive Truvada at no cost through July 31, 2025.
- To qualify for the exception program, the individual's healthcare provider must submit a letter of medical necessity attesting that the individual was assigned female at birth, based on their clinical judgment, TRUVADA for PrEP is the most clinically appropriate product for the individual, and the individual is unable to afford a generic alternative. To enroll/re-enroll, individuals or their healthcare provider must either call Advancing Access or fax a completed enrollment form and letter of medical necessity. Please contact an Advancing Access representative at 1-800-226-2056 for enrollment assistance. The exception program will end on July 31, 2025.

What is NOT changing:

- All other Gilead Advancing Access patient support offerings will remain available for individuals prescribed TRUVADA[®], EMTRIVA[®], TYBOST[®] and COMPLERA[®]. These include general coverage inquiries, benefits investigation requests, alternate coverage

assessments, and co-pay coupon support for commercially insured, eligible individuals.

- Gilead HIV prevention and HIV treatment medications continue to be available through our PAP/MAP free medication programs, including BIKTARVY®, DESCOVY®, GENVOYA®, ODEFSEY®, STRIBILD®, SUNLENCA® (for HTE patients only).

Impact to CURRENTLY enrolled individuals:

- Currently enrolled individuals may continue to receive TRUVADA®, EMTRIVA®, TYBOST® and COMPLERA® free of charge until January 31, 2025. If your patient's enrollment period ends prior to January 31, 2025, they may re-enroll to continue to receive their free medication until January 31, 2025, if all other program eligibility criteria is met.
- The Advancing Access PAP/MAP will continue to provide free medication assistance for other Gilead HIV prevention and HIV treatment medications. To change medications, simply send a new prescription for an alternative Gilead HIV prevention or HIV treatment medication to the individual's pharmacy of choice.

Impact to NEW program enrollees:

- Individuals prescribed TRUVADA®, EMTRIVA®, TYBOST® and COMPLERA® that are new to our PAP/MAP may enroll in the program by December 31, 2024, to receive their medication free of charge until January 31, 2025.

We will notify individuals impacted by the program changes on October 15, 2024. To support this transition, Advancing Access representatives are available to help with identifying healthcare coverage and financial support options that may be available to your patient. We also encourage you to work with your patients affected by this update to assess alternative medication options that may be available to them.

If you need assistance identifying your patients affected by this update, or have questions about this change, please contact us at 1-800-226-2056, Monday through Friday between 9:00 AM and 8:00 PM EST.

Sincerely,
Advancing Access